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Overline: Gut Microbiota 
 
 
One Sentence Summary: Gut microbes transplanted into germ free mice improve 
skeletal muscle mass and strength. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accessible Summary 
 
 
Abstract  
The functional interactions between the gut microbiota  and the host are important for 
host physiology, homeostasis and sustained health. Germ-free mice, not exposed to 
microbes, displayed reduced skeletal muscle mass due to skeletal muscle atrophy when 
compared to pathogen-free mice that had gut microbes. Skeletal muscle of germ-free 
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mice display muscle atrophy, decreased expression of insulin-like-growth factor 1 (Igf1) 
and reduced transcription of genes associated with skeletal muscle growth and 
mitochondrial function. NMR spectrometry analysis of skeletal muscle, liver, and serum 
from germ-free mice revealed multiple changes in the amounts of amino acids, including 
glycine and alanine compared to the spectrum observed in mice exposed to microbes . 
Germ-free mice also had reduced serum choline, the precursor of acetylcholine, the key 
neurotransmitter between muscle and nerve at the neuromuscular junction. Reduced 
expression of Rapsyn and Lrp4, two proteins important for neuromuscular junction 
assembly and function were also observed in muscle from germ free mice. Transplanting 
germ-free mice with gut microbiota from pathogen-free mice, resulted in an increase in 
skeletal muscle mass, reduction in atrophy markers, improved oxidative metabolic 
capacity of muscle and elevated expression of the neuromotor junction assembly genes 
Rapsyn and Lrp4. Exposing germ-free mice to microbe metabolites such as short chain 
fatty acids, in part reversed skeletal muscle impairments. Our results suggest a role for 
the gut microbiota in regulating skeletal muscle mass and function in mice. 
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Introduction 
Skeletal muscle function is regulated by the central nervous system through 
neurotransmission at neuromuscular junctions (NMJs). NMJs are highly specialized 
chemical synapses formed between motor neurons and skeletal muscle fibers (1). Skeletal 
muscle displays marked plasticity being able to respond to a variety of environmental 
cues, such as exercise and nutrition. Skeletal muscle is also the major site of insulin-
stimulated glucose uptake and fatty acid oxidation emphasizing its key role in 
metabolism. Reduced skeletal muscle mass and function are associated with metabolic 
disorders (2) and sarcopenia (3), underscoring its role in maintenance of health.  
 It has been established that the gut microbiota influences host health in part due to 
its co-evolvement with the host to meet mutually beneficial biochemical and biological 
needs (4). There are many studies investigating how the gut microbiota influences liver 
and intestinal metabolism, immunity, and behavior (5–8). However, few studies have 
reported on how the gut microbiota regulates one of the dominant metabolic organs in the 
body, skeletal muscle. Here, we present evidence from germ-free and pathogen-free mice 
that the gut microbiota influences skeletal muscle mass and function. 
 
Results  
Gut microbes modulate skeletal muscle mass in mice 
Germ-free mice (GF) that lacked gut microbiota displayed reduced skeletal muscle mass 
compared to pathogen–free (PF) control mice that had gut microbiota (Fig. 1A). . 
Transplanting germ-free mice with the gut microbiota of pathogen-free mice (henceforth 
mentioned as conventionalized germ-free mice, C-GF) restored muscle mass in the 
transplanted animals (C-GF) (Fig. 1A). Histological examination of the tibialis anterior 
(fast oxidative) muscle revealed a trend towards fewer but larger muscle fibers (>2000–
3000 m2 cross-sectional fiber area) in germ-free mice compared to pathogen-free mice 
(Fig. S1A and B). In addition, reduced expression of the myosin heavy chain genes 
MyHC IIa, IIb, and IIx were observed in germ-free muscle compared to pathogen-free 
tibialis anterior muscle (Fig. 1B). A similar trend was also observed in the soleus (slow-
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oxidative) muscle and the extensor digitorum longus (fast-glycolytic) muscle of germ-
free mice compared to pathogen-free mice (Fig. S1C and D). Furthermore, we observed 
increased expression of Atrogin-1 and MuRF-1 encoding E3 ubiquitin ligases, known to 
be involved in muscle atrophy, in the tibialis anterior muscle of germ-free mice compared 
to pathogen-free mice (Fig. 1C, 1E, and 1F). Transplanting germ-free mice with the gut 
microbiota of pathogen-free mice reduced the expression of  MuRF-1 and Atrogin-1 in 
anterior tibialis muscle of the C-GF mice. The expression of Atrogin-1 and MuRf-1 are 
known to be regulated by FoxO transcription factors (9). While elevated expression of 
FoxO3 expression was observed in the tibialis anterior muscle of germ-free mice, the 
expression was normalized in the conventionalized germ-free mice (Fig. 1C). The energy 
sensor AMP-activated protein kinase (AMPK) controls muscle fiber size by activating 
the FoxO-mediated protein degradation pathway (10). Further analysis of the tibialis 
anterior muscle from germ-free mice revealed an increase in phosphorylation of the 
catalytic domain (Thr172) of AMPK (Fig. 1E and F). It has been reported that Atrogin-1 
expression regulates MyoD expression in skeletal muscle under atrophy conditions (12). 
We observed reduced expression of key muscle genes that regulate skeletal muscle 
differentiation, such as MyoD and Myogenin, in germ-free skeletal muscle compared to 
pathogen-free skeletal muscle (Fig. 1D). Similar trends in increased expression of 
atrophy markers such as Atrogin-1 and MuRF-1 with a concomitant downregulation of 
MyoD expression were also observed in soleus (slow oxidative) muscle and extensor 
digitorum longus (fast glycolytic) muscle of germ-free mice (Fig. S1 E-H).  
Glucocorticoids are known to induce skeletal muscle atrophy under various 
pathological conditions (13). The transcription factor Kruppel Like Factor 15 (KLF15) is 
one of the target genes activated by the glucocorticoid receptor and is involved in the 
regulation of several metabolic processes in skeletal muscle including the upregulation of 
branched-chain aminotransferase 2 (BCAT2), which in turn induces the degradation of 
branched-chain amino acids (BCAAs) (14). A surge in corticosterone concentrations was 
observed in serum of germ-free mice (Fig. 2A), along with up-regulation of Klf15 
expression in tibialis anterior muscle of germ-free (Fig. 2B). The observed muscle 
atrophy in germ-free mice was also associated with activation of the enzymes involved in 
the BCAA catabolic pathway. BCAAs are trans-aminated by BCAT2 to generate 
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branched-chain α-keto acids, which in turn are subjected to oxidative decarboxylation by 
branched-chain α-keto acid dehydrogenase (BCKDH) to produce Coenzyme A esters. 
BCKDH activity is negatively regulated by the BCKDH kinase (BCKDK). Increased 
gene expression of Bcat and Bckdh were observed in  tibialis anterior muscle of germ-
free mice, whereas the expression of the inhibitor Bckdk was reduced suggesting 
increased BCAA catabolism in skeletal muscle tissue of germ-free mice (Fig. 2C).  
Skeletal muscle mass is maintained by the balance between protein synthesis and 
protein degradation. To monitor potential decline in the protein synthesis pathway, we 
assessed the Igf1-Akt-mTOR growth-promoting pathway. As can be seen (Fig. 2D), 
while the expression of the insulin-like-growth factor 1 gene (Igf1) was impaired in 
tibialis anterior muscle of germ-free mice, the Igf1 expression was normalized when 
germ-free mice were transplanted with gut microbiota of pathogen-free mice. Notably, 
Igf1 protein levels remain unaltered in the serum of germ-free mice (Fig. S1I), suggesting 
additional Igf1 regulatory loop(s), possibly involving the Igf binding proteins (IGFBPs) 
that are known to regulate Igf1 functions. Indeed, of the six IGFBPs, we observed 
elevation of expression of the Igfbp3 gene in tibialis anterior muscle of germ-free mice 
compared to pathogen-free mice and C-GF mice (Fig. 2D), in line with a previous 
observation (15). Increased expression of Igfbp3 is known to exert an inhibitory effect on 
skeletal muscle growth suggesting on regulatory loop to explain the reduced muscle mass 
in skeletal muscle of germ-free mice (16). However, the activation profile of Akt, mTOR, 
and its downstream effector, the S6 ribosomal protein, were unaffected in muscles from 
germ-free mice (Fig. S1J and K).  
 
Altered metabolism in skeletal muscle of Germ-free mice 
Given that skeletal muscle of germ-free mice showed signs of atrophy, we next 
investigated the oxidative metabolic capacity of skeletal muscle. Histological staining 
revealed reduced activity of the mitochondrial enzyme succinate dehydrogenase (SDH) 
(Fig. 3A) and expression of the Sdh gene (Fig. 3B) in germ-free muscle compared  to that 
observed in muscle from pathogen-free mice. Mitochondrial DNA content was also 
reduced in germ-free muscle, but was restored when transplanted with gut microbiota 
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from pathogen-free mice (Fig. 3C). Additionally, we observed reduced gene expression 
of mitochondrial biogenesis markers, such as peroxisome proliferator-activated receptor 
gamma coactivator1-alpha (Pgc1α) and mitochondrial transcription factor A (Tfam) in  
skeletal muscle of germ-free mice (Fig. 3D). Moreover, we noticed reduced expression of 
genes encoding different mitochondrial oxidative phosphorylation complexes in skeletal 
muscle of germ-free mice, including genes encoding cytochrome oxidase subunits of 
complex IV (CoxVa, CoxVIIb, and CytC), known to be involved in the electron transport 
chain (Fig. 3E). Similar observations supporting dysfunctional mitochondrial biogenesis 
and oxidative capacity were also observed in two other skeletal muscle subtypes, soleus 
(oxidative) and extensor digitorum longus (glycolytic) muscle of germ-free mice (Fig. S2 
A-D). The protein expression profile of the different oxidative phosphorylation 
(OXPHOS) complexes of the electron transport chain (Fig S6A) were also altered in 
muscle from germ-free mice. Despite a possible reduction in oxidative metabolic 
capacity, germ-free mice performed as well as pathogen-free mice when challenged to 
exercise until exhaustion (Fig. S2E). 
 These results prompted us to undertake further metabolic analyses of germ-free 
mice. Analysis of serum metabolic markers revealed reduced quantities of glucose and 
insulin in germ-free mice compared to pathogen-free mice (Fig. S2F). Futher 
investigation of metabolic pathways for fatty acid and glucose metabolism in germ-free 
mice muscle, revealed reduced expression of glycolytic genes encoding the enzymes 
phosphofructokinase (Pfk), pyruvate kinase (Pk), lactate dehydrogenase (Ldh), and 
pyruvate dehydrogenase (Pdh) in tibialis anterior muscle from germ-free mice. 
Expressions of these enzymes were restored when germ-free mice were transplanted with 
the gut microbiota of pathogen-free mice (Fig. 3F). A similar trend of reduced expression 
of glycolytic genes was also observed in the soleus and extensor digitorum longus 
muscles of germ-free mice (Fig. S2D and E). No differences in expression of genes 
encoding medium-chain acyl-CoA dehydrogenase (Mcad) and muscle specific carnitine 
palmitoyltransferase1b (mCpt1b) involved in fatty acid oxidation (Fig. 3G) as well as 
phosphorylation of acetyl Co-A carboxylase (Fig. S2I and J) were observed in  tibialis 
anterior muscle of germ-free mice. Cholesterol and free fatty acids in serum remained 
unaltered in germ-free mice compared to pathogen-free mice (Fig. S2F). Further analysis 
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of glucose uptake in skeletal muscles, using FDG-PET/MRI imaging, revealed no 
obvious differences in glucose uptake for the back muscles and hindleg muscles of germ-
free when compared to pathogen-free mice (Fig. S2K and L). However, we observed an 
increased accumulation of glycogen in quadriceps (fast glycolytic) of muscles in germ-
free mice(Fig. 3H), implying possible impaired utilization of glucose by the quadriceps 
muscle by germ-free mice.  
To further corroborate our findings, we assessed whether disruption of the gut 
microbiota–host environment, using antibiotics had effects on skeletal muscle. We 
monitored muscle samples from pathogen-free mice exposed to low-dose penicillin in 
order to examine consequences of disruption of host metabolic functions mediated by 
alterations in microbial community composition (18, 19). Whereas low-dose penicillin 
increased FoxO3 gene expression and reduced  MyoD gene expression in skeletal muscle 
of pathogen-free mice  (Fig. S3A), the expression of Atrogin-1, MuRf-1, Pgc1α and Tfam 
genes remained largely unaffected under these experimental conditions (Fig. S3B). 
However, electron transport chain genes (CoxVa, CoxVIIb, and CytC) were 
downregulated in pathogen-free mice treated with low-dose penicillin (Fig. S3C) 
indicating reduced oxidative metabolic capacity in skeletal muscle.  
 
Altered metabolites in skeletal muscle, liver, and serum of Germ-free mice 
To characterize the metabolic phenotype of germ-free mice in detail, proton NMR spectra 
were measured at 600 MHz for skeletal muscle, liver, and serum samples from germ-free 
mice, pathogen-free mice and conventionalized germ-free mice with gut microbiota from 
pathogen-free mice  (Fig. 4). Cross-validated principal component analysis and 
orthogonal partial least squares analysis models revealed differences in 1H NMR 
metabolic profiles for skeletal muscle, liver, and serum from germ-free mice compared to 
pathogen-free mice and from germ-free mice compared to conventionalized germ-free 
mice transplanted with gut microbiota from pathogen-free mice (Fig. S4A, B and C). 
Transplanting germ-free mice with gut microbiota from pathogen-free mice  normalized 
the metabolite profiles to that observed in pathogen-free mice.   
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Our metabolic profiling identified large quantities of amino acids such as alanine 
and glycine in skeletal muscle of germ-free mice (Fig. 4A and Table 1). The expression 
of the gene encoding alanine transaminase (Alt) that results in transamination of alanine 
was also increased in muscle of germ-free mice (Fig. S5A). Typically, the amino acids 
alanine and glycine, and their carbon skeletons, enter different metabolic pathways to 
generate energy. However, we did not observe any change in ATP concentrations in the 
skeletal muscle of germ-free mice compared to the levels in pathogen-free mice and C-
GF mice transplanted with gut microbiota from pathogen-free mice  (Fig. S5B). We next 
tested whether higher alanine levels in the muscle of germ-free mice served as a source 
for hepatic gluconeogenesis through the glucose–alanine shuttle. Reduced alanine (Fig. 
3B and Table 1) along with low expression of the gene encoding glucose-6-phosphatase 
gene (G6Pase), a gluconeogenic marker, were observed in the liver of germ-free mice 
when compared to the pathogen- free mice. (Fig. S5C).  
 A large amount of glycine was observed in skeletal muscle of germ-free mice 
(Fig. 3A and Table 1). Apart from a possible increase in protein degradation of muscle 
tissue, glycine can be derived from intermediates of glycolysis (21). However, no 
changes in expression of genes encoding key enzymes of this intermediate pathway, such 
as phosphoglycerate dehydrogenase (Phgdh) and serine hydroxymethyltransferases 
(Shmt1 and Shmt2) were observed in the muscle of germ-free mice (Fig. S5D). Glycine 
can also be generated from choline via betaine, dimethylglycine, and sarcosine. Reduced 
quantities of choline and dimethylglycine along with higher amounts of glycine were 
found in the serum of germ-free mice (Fig. 4C and Table 1). Intermediates in the choline 
metabolic pathway, glycerophosphocholine and betaine, were also reduced in the liver of 
germ-free mice (Fig. 4B and Table 1). However, no changes in expression of the genes 
encoding the enzymes involved in these intermediate steps---choline dehydrogenase 
(Chdh), betaine homocysteine s-methyltransferase (Bhmt), Bhmt2, and sarcosine 
dehydrogenase (Sardh) -were observed in the skeletal muscle of germ-free  when 
compared to pathogen-free mice (Fig. S5E).  
The metabolite profile of liver in germ-free mice was characterized by high taurine, 
hypotaurine, and tauro-conjugated bile acids (taurocholic acid) affecting bile acid 
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metabolism. We also observed increased dimethylamine, a product of choline 
degradation in the liver of germ-free mouse (Fig. 4B, Table 1). Furthermore, 
glycerophosphocholine, betaine (tri-methyl-glycine), and oxidized glutathione were also 
present in lower amounts in liver of germ-free mice, indicating potential perturbation of 
the cysteine metabolic pathway even though the amount of sarcosine remained high. In 
addition, glutamine, alanine, leucine, and valine along with glutamate were reduced in the 
liver of germ-free mice as compared to pathogen-free mice. Pyruvate was lower in the 
liver of germ-free mice as compared to pathogen-free mice. Expression profiling of genes 
encoding enzymes involved in mitochondrial oxidative metabolism as well as glucose 
metabolism revealed reduced expression of several genes involved in these pathways 
indicating metabolic dysfunction in liver of germ-free mice compared to that of 
pathogen-free mice (Fig. S5F, G). 
Glycine amounts were high in serum and muscle of germ-free mice compared to 
pathogen-free or conventionalized mice transplanted with gut microbiota of pathogen-
free mice (Fig. 4C, Table 1). However, amounts of choline, trimethylamine, and 
dimethylglycine were lower in serum of germ-free compared to pathogen-free and 
transplanted germ-free mice. In addition, acetate, pyruvate and 3-hydroxybutyrate were 
lower in serum of germ-free mice. We also observed differences in serum lipid profiles 
with high amounts of Very-Low-Density-Lipoproteins (VLDL) and low amounts of Low-
Density-Lipoproteins (LDL) in germ-free mice compared to pathogen-free mice, in 
agreement with an earlier report (24). Overall, the metabolomics data indicates disrupted 
energy homeostasis in germ-free mice compared to pathogen-free mice, with a marked 
perturbation of the amino acid metabolic pathway (Fig. 5 4). 
 
Altered expression of Neuro-Muscular Junction (NMJ) genes in Germ-free mice  
Given that we observed low quantities of choline in the serum of GF mice (Fig. 4C, Table 
1), and that choline is a substrate for the derivation of the neurotransmitter acetylcholine 
and essential for membrane integrity (25), we screened an array of molecules that affect 
NMJ development and function including acetylcholine receptors (26). We observed 
reduced expression of genes encoding different acetylcholine receptor subunits (Chrna1, 
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Chrnb, Chrne, and Chrnd) in tibialis anterior muscle of germ-free mice(Fig. 6A) 
suggesting a potential impairment of assembly of acetylcholine receptors. We, therefore, 
monitored the expression of genes associated with formation, maturation, and 
maintenance of NMJs, including Rapsyn, a 43kDa receptor-associated synaptic protein 
(27) and the low-density lipoprotein receptor related protein 4 (Lrp4), both reported to be 
important for the development and assembly of acetylcholine receptors in NMJs (28). 
Expression of both Rapsyn and Lrp4 genes were reduced in GF mice, and this change 
was reversed when germ-free mice were transplanted with the gut microbiota of 
pathogen-free mice (Fig. 6B). Lrp4 associates with muscle-specific kinase (MuSK) to 
form a receptor complex necessary for agrin to bind (29). While we noted elevated 
expression of the MuSK gene, no change in expression of the Agrn gene, encoding its 
ligand agrin, was observed in muscle of germ-free mice (Fig. 6B). The reduced 
expression of the gene encoding troponin in skeletal musle of germ-free mice suggested 
possible impairment in myofiber contractility (Fig. 6C). We, therefore, evaluated muscle 
strength in germ-free mice. Germ-free mice displayed reduced muscle strength compared 
to muscle from pathogen-free mice when examined in a weights test (Fig. 6D). Germ-free 
mice also exhibited reduced locomotor and rearing activity compared to pathogen-free 
mice (Fig. 6E and F).  
 
Bacterial metabolites influence skeletal muscle mass in Germ-free mice 
Germ-free mice have elevated hypothalamic–pituitary–adrenal axis activity as shown by 
increased serum corticosterone (Fig. 2A). We therefore used an established in vitro cell 
culture model (30) to study the effects of microbial metabolites on muscle atrophy, 
induced by glucocorticoids. Dexamethasone treatment induced Atrogin-1 expression in 
differentiated C2C12 myotubes in vitro (Fig. 7A). A cocktail of short chain fatty acids 
(SCFAs), such as those generated by microbial fermentation of dietary polysaccharides, 
reduced the effect of dexamethasone on Atrogin-1 expression (Fig. 7A). We also 
observed that SCFAs enhanced the expression of Pgc1a, Tfam (Fig. 7B), CoxVa and 
CoxVIIb when administered to differentiated C2C12 myotubes in vitro (Fig. 7C), 
indicating that microbial metabolites can positively regulate oxidative metabolism in 
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skeletal muscle of mice under these experimental conditions. In addition, we monitored 
the effect of the SCFA cocktail on both basal and maximal cellular respiration. Carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) stimulated respiration in 
mitochondria by uncoupling ATP synthesis from electron transport in C2C12 myotubes 
(Fig. S6 B and C). Under  FCCP-stimulation conditions, treatment with the SCFA 
cocktail resulted in decreased oxygen consumption rate (Fig. S6 B) and an increased 
extracellular acidification rate (Fig. S6 C) in C2C12 myotubes implying a metabolic 
switch from oxidative phosphorylation to a glycolytic mode of energy production.  
 We also treated GF mice in vivo with a cocktail of SCFAs. We observed a trend 
of increased skeletal muscle mass, particularly in the case of the gastrocnemius muscle 
(Fig. 7D) in germ-free mice treated with SCFAs compared to untreated germ-free mice. 
Furthermore, in vivo treatment of germ-free mice with SCFAs mice, reduced the 
expression of Atrogin-1 (Fig. 7E) although expression of MuRf-1 was higher in tibialis 
anterior muscle (Fig. 7E). We also noted increased expression of MyoD, a marker 
associated with myogenesis, in tibialis anterior muscle of SCFA-treated germ-free mice 
compared to untreated germ-free mice. (Fig. 7E). However, we did not observe changes 
in expression of genes encoding the mitochondrial transcription factors Pgc1α and Tfam 
(Fig. 7F) or electron transport chain proteins CoxVa, CoxVIIb, and CytC (Fig. 7G) in the 
tibialis anterior muscle of SCFA-treated germ free mice compared to untreated mice. 
Importantly, SCFA treatment improved muscle strength of germ-free mice in the weights 
test compared to untreated GF mice (Fig. 7H). No alterations in gene expression of the 
NMJ markers, Rapsyn and MuSK, were observed in tibialis anterior muscle of SCFA-
treated mice compared to untreated GF mice (Fig. 7I).  
 
Discussion  
Here we show  that the gut microbiota contributes to modulate skeletal muscle mass and 
function in mice. Germ-free mice displayed reduced muscle mass and signs of muscle 
atrophy through increased expression of FoxO, Atrogin-1, Murf-1 and MyoD along with 
with reduced muscle strength. Activation of AMPK in germ-free mouse muscle further 
suggests that the AMPK-FoxO3-atrogenes cascade could be one possible signaling 
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pathway to explain, at least in part, the atrophy observed in germ-free muscle tissues. 
Similar elevation in AMPK phosphorylation in gastrocnemius muscle of germ-free mice 
fed on a Western diet for 5 weeks was previously reported (11), but not from mice in the 
normal physiological setting as shown in our study. In addition, our results suggest 
alteration in IGF1 protein expression locally in the muscle of germ-free mice, rather than 
peripheral effects of circulating IGF-1. The Akt-mTOR pathway appeared to be 
unaffected in muscle of germ-free mice. This suggests that protein degradation exceeded 
protein synthesis, which in part could contribute to the reduced skeletal muscle mass 
observed in germ-free mice. Our observations of increased corticosterone concentrations 
in serum, induction of Klf15 gene expression and activation of the BCAA pathway 
indicate a possible HPA-glucocorticoid driven atrophy of skeletal muscle mass in germ-
free mice. Skeletal muscle atrophy observed in mice maintained under germ-free 
conditions, thus, might be the consequence of dysregulation in several signaling 
pathways controlling skeletal muscle mass. The reduced levels of choline in serum, along 
with marked changes of gene expression of NMJ linked proteins in muscle of germ-free 
mice, defective locomotion and grip strength capacity, are therefore possible additional 
factors affecting muscle mass and function in germ-free mice. Furthermore, our 
observations from muscles of different metabolic subtypes suggest that the phenotypic 
changes observed in germ-free mice are not unique to muscle with specific metabolic 
characteristic but have a consistent impact on skeletal muscle as a consequence of the 
absence of gut microbiota. 
Gut microbes synthesize amino acids and make them available to the host (35). 
Analyses of skeletal muscle, liver, and serum metabolites revealed altered amino acid 
metabolism in GF mice. Glycine and alanine were increased in GF compared to PF 
mouse skeletal muscle. Glycine has important implications in skeletal muscle wasting 
(36), acts as an energy source for muscle (37) and is also induced in response to 
mitochondrial stress (22). BCAA catabolism is associated with skeletal muscle protein 
breakdown and correlated with low leucine and valine concentrations in liver tissue and 
serum of germ-free mice. Decreased quantities of BCAAs, as seen in liver and serum of 
germ-free mice, have been associated with severe catabolic conditions, such as cachexia 
in terminal stages of cancer (38, 39). BCAAs not only serve as an alternate energy 
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substrate but also are known to improve nitrogen retention and protein synthesis (40). 
They represent the major nitrogen source for alanine synthesis in muscle. Prior to their 
usage as fuel and being fed into the tricarboxylic acid cycle, BCAAs undergo a series of 
trans-amination steps eventually resulting in production of alanine. High quantities of 
alanine along with increased Alt gene expression observed in msucle of germ-free mice  
might thus be a consequence of muscle protein breakdown resulting in increased 
bioavailability of amino acids to cope with the stress generated due to the absence of  gut 
microbiota.   
 Many interactions between the host and its gut microbiota  are mediated by 
SCFAs generated from the bacterial fermentation of dietary polysaccharides (31-33). 
From our observations, SCFAs support, in part, skeletal muscle function by preventing 
atrophy and increasing muscular strength. However, the diverse biosynthetic activity of 
the gut microbiota beyond providing SCFAs to be used by the host as an energy source 
may explain why only SCFAs supplementation in germ-free mice could not fully rescue 
the muscle impairment phenotype. Microbes and their metabolites are likely to engage 
multiple converging pathways to regulate host muscle growth and function. Additional 
microbial products other than SCFAs might also be involved in skeletal muscle growth 
and function. Our study has elucidated several underlying molecular mechanisms 
supporting regulation of skeletal muscle mass and function in germ-free mice. While, 
germ-free mice, an animal model used to study microbe-host interactions is an artificial 
system, these mice, devoid of exposure to living microbes, provide opportunities to study 
microbe-host interactions in vivo. Deficits in physiological and metabolic processes due 
to maintaining mice under germ-free conditions are well documented. The use of low 
dose antibiotic treatment helped us to support our observations in germ-free mice that 
implied the lack of gut microbiota in reduced muscle mass and function. However, the 
muscle tissue samples collected from the antibiotic experiment was obtained from 
pathogen-free mice  raised in a different animal facility and hence, should be interpreted 
cautiously. While our observations also suggest that the communication between muscle 
cells and nerve cells via the NMJs may be impaired in germ-free condition, further 
experiments, including physiological experiments are required to reach definitive 
conclusion. Additional studies are also warranted to identify specific bacterial produced 
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metabolites or other microbial products to influence skeletal muscle growth and function. 
In conclusion, we have demonstrated the existence of a gut microbiota-skeletal muscle 
axis that opens for further mechanistic and physiological studies for a better 
understanding of mechanisms regulating this highly important metabolic organ by the gut 
microbiota.  
  
 17 
Materials and Methods 
Study design 
The objective of this study was to elucidate the functional interactions between the gut 
microbiota and the host in the regulation of skeletal muscle mass and function. Muscle 
was assessed in germ-free mice and pathogen-free mice maintained on autoclaved R36 
Lactamin chow (Lactamin), provided with sterile drinking water ad libitum, and kept 
under 12-h light/dark cycles in state-of-art germ-free animal housing facilities. Skeletal 
muscle mass was examined and differences in expression of genes encoding different cell 
signaling molecules that regulate muscle mass were characterized. Detailed metabolic 
characterization was also performed using NMR spectrometric analyses of skeletal 
muscle, liver and serum samples. The influence of the gut microbiota  on NMJs was also 
examined by analyzing expression of NMJ proteins and testing mouse muscle strength in 
the grip strength test in germ-free mice compared to pathogen-free mice. The gut 
microbiota’s role in muscle mass and function was further analysed by transplanting 
germ-free mice with the gut microbiota of pathogen-free animals or treating them with  
microbial metabolites (short chain fatty acids). We examined the effects alterations of gut 
microbiota. composition on muscle by treating pathogen-free mice with low-dose 
penicillin. Three independent cohorts of pathogen-free, germ-free and conventionalized 
germ-free groups have been used with a minimum of 5 mice included in each 
experimental group. Blinding of researchers about the knowledge of group allocation has 
been ensured along with randomization of the groups to limit the occurrence of conscious 
and unconscious bias during experimentation. .  
Animals 
Germ-free and pathogen-free C57BL/6J male mice (6 to 8 weeks old) were raised in the 
Core Facility for Germ-Free Research, Karolinska Institutet, Sweden, and LKC School of 
Medicine GF research facility, Singapore, in accordance with the regulatory standards of 
each institution. All experiments were approved by respective local ethical committees. 
Germ-free mice were raised in special sterile isolators. Isolator sterility was analyzed 
weekly by plating fecal homogenates onto different types of agar plates to detect aerobic 
and anaerobic bacteria and fungi. To transplant germ-free with gut microbiota of 
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pathogen-free mice, germ-free mice were conventionalized (C-GF) post-weaning by 
gavage of 100 µl of homogenate generated by dissolving two fecal pellets from pathogen-
free mice in 1 ml of PBS. After gavage, C-GF mice were co-housed with pathogen-free 
mice for 21 days before they were sacrificed. The control group was gavaged with sterile 
PBS. Mice were sacrificed under isoflurane anesthesia. All animals were maintained on 
autoclaved R36 Lactamin chow (Lactamin), provided with sterile drinking water ad 
libitum, and kept under 12-h light/dark cycles. Three independent cohorts of pathogen-
free, germ-free and germ-free mice transplanted with gut microbiota of pathogen-free 
mice were used with a minimum of 5 mice in each group. The behavioral assays were 
conducted in accordance with national guidelines for the care and use of laboratory 
animals for scientific purposes, with approved protocols from the Institutional Animal 
Care and Use Committees of Duke-NUS Graduate Medical School, Singapore.  
 SCFA treatment of germ-free mice. Germ-free mice (6–8 weeks of age) were 
treated with a cocktail of SCFA as per a previously published protocol (47). Briefly, mice 
(n=6 per group) were fed a mix of SCFA (67.5 mM sodium acetate, 40 mM sodium 
butyrate, 25.9 mM sodium propionate) in their drinking water for a period of 4 weeks. No 
decrease in water intake was noted, and mice were monitored for signs of dehydration. 
Sterility of the GF and SCFA-treated GF cohort was assessed twice a week and 
maintained throughout this study. After 4 weeks, mice were euthanized by inhalation of 
isoflurane and sacrificed, and muscles were harvested. TA muscles were used for qPCR 
analyses. 
 Antibiotic treatment.C57BL/6J mice were given low-dose penicillin (1 µg/g 
body weight, LDP) via drinking water or no antibiotics (control) for 4 weeks post-
weaning as previously reported (18).  
Weights test 
Weight tests were performed to measure muscular strength as described previously (41).. 
Briefly, each mouse was held by the middle of the tail and slowly lowered to grasp the first 
weight (26 g) in a well-lit fume hood. Upon grasping the wire scale, mice were raised until 
the weight was fully raised above the bench. The criterion was met if the mouse could hold 
the weight for 3 s. If the weight was dropped in before 3 s, the time was noted, and the 
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mouse rested for 10 s before performing a repeat trial. Each mouse was allowed a maximum 
of 5 trials before being assigned the maximum time achieved; if it successfully held the 
weight for 3 s, it was allowed to progress to the next heaviest weight. The apparatus 
comprised 6 weights, weighing 26g, 33g, 44g, 63g, 82g, and 100g. All cage mates of each 
group were tested using a given weight before progressing to the next-heaviest weight. The 
total score for each mouse was then calculated as the product of the number of links in the 
heaviest chain held for the full 3 s, multiplied by the time (s) it was held. 
 
Activity in the open field task 
Locomotor and rearing activities were monitored for individual mice using an automated 
Omnitech Digiscan apparatus (AccuScan Instruments, Columbus, OH, USA), as 
described previously (42). Mice were monitored in the open field for 60 min. Locomotion 
was measured as total distance traveled and rearing as vertical activity. 
 
Treadmill running task 
Eight-week-old mice were subjected to exercise on a treadmill (Columbus, OH, USA) 
using a previously reported exercise regimen (43). Mice in all groups were acclimated to 
moderate treadmill running (10 m/min for 15 min; 5 incline) for 2 days. After 
acclimation, for the exercise test, mice ran on a treadmill set at a gradually increasing 
speed from 0 to 15 m/min and then maintained at a constant speed until exhaustion. Mice 
were removed from the treadmill upon exhaustion and had free access to food and water 
after the running protocol was completed. Mice were sacrificed 3 h after the exercise test. 
PET-MRI 
Mice were fasted for 4 h prior to the imaging session. They were imaged under anesthesia 
using a nanoScan PET/MRI scanner (Mediso, Hungary) under anesthesia (44). The whole 
body MRI images were acquired with the 1 T MRI component of the nanoScan PET/MRI 
scanner. All images and data analyses for the FDG PET images were performed using 
PMOD (version 3.5; PMOD Technologies).  
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PET acquisition: A 40 min long 3D static PET scan was performed after IV injection of 
FDG; the animals were moving freely during the waiting period. The injected 
radioactivity was 10.0–15 MBq, and the maximum injected volume was 0.1 ml. 
MRI acquisition. A 35-mm mouse whole body coil was used for the MRI scan. 0.8 mm 
slices were obtained using a 2D T1 SD coronal sequence with 100-mm square FOV, 256 
× 256 matrix, 1034-ms repetition time (TR), 12.4-ms echo time (TE), and 90 degree flip 
angle.  
Image analysis: The PET images were first automatically registered to the MRI images 
using the FUSION tool in PMOD. The MRI images were then used for the manual 
delineation of volumes of interest (VOI). VOIs for hind leg muscle and back muscle were 
used for the analysis. 
 
Cell culture and treatments 
Murine C2C12 myoblasts (ATCC, USA) were cultured and were considered myotubes 
after 96 h of differentiation. Differentiated cells were then treated with 1 mM 
dexamethasone (Dex, Sigma-Aldrich, USA) for 24h, along with a cocktail of SCFAs, 
such as acetate, propionate, and butyrate, based on the molar ratio of their availability in 
the plasma (60:25:15 for acetate: propionate: butyrate) (45).  
In vitro cellular respiration assay. 
Oxygen consumption in differentiated C2C12 cells in response to bacterial metabolites 
(i.e., SCFAs) was measured using XF96 equipment (Seahorse Bioscience), as described 
previously (46). 
 
Metabolomic analyses of skeletal muscle, liver, and serum.  
1H NMR spectroscopy was performed on the aqueous-phase extracts from skeletal 
muscle (gastrocnemius), liver, and serum at 300 K on a Bruker 600 MHz spectrometer 
(Bruker Biospin, Karlsruhe, Germany) as described in (48). Metabolic network was 
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generated using the freely available MetaboNetworks software (49).  
Sample treatment. Hydrophilic metabolites were extracted from liver and skeletal 
muscle (gastrocnemius). Samples were homogenized (64,000 rpm, 2 min) in 7.5 ml 
chloroform:methanol (2:1). The homogenate was combined with 1 ml water, mixed by 
vortexing, and centrifuged at 13,000 ×g for 5 min. The upper aqueous phase was 
separated from the lower organic phase and dried using nitrogen gas. Frozen serum 
samples (-80○C) were thawed and then centrifuged at 2700 ×g for 10 min to remove 
particulates and precipitated proteins. 300 μl of individual serum samples was prepared 
with pH 7.4 phosphate buffer, as described previously for high resolution 1H NMR 
spectroscopy (48).  
1H NMR metabolic profiling analysis. The hydrophilic phase of liver and skeletal 
muscle was reconstituted in 540 μl of D2O and 60 μl of phosphate buffer (pH 7.4, 80% 
D2O) containing 1 mM of the internal standard, 3-(trimethylsilyl)-[2,2,3,3,-2H4]-
propionic acid (TSP). 1H NMR spectroscopy was performed on the aquose phase extracts 
at 300 K on a Bruker 600 MHz spectrometer (Bruker Biospin, Karlsruhe, Germany) 
using the following standard one-dimensional pulse sequence with saturation of the water 
resonance: relaxation delay (RD) – gz,1 – 90° – t – 90° – tm – gz,2 – 90° – acquisition 
time (ACQ), where RD is the relaxation delay, 90° represents the applied 90° radio 
frequency (RF) pulse, t1 is an inter-pulse delay set to a fixed interval of 4 μs; RD was 2 s 
and tm (mixing time) was 100 ms (48). Water suppression was achieved through 
irradiation of the water signal during RD and tm. For the the liver and muscle samples, 
each spectrum was acquired using 4 dummy scans followed by 32 scans and collected 
into 64 K data points. A spectral width of 20,000 Hz was used for all samples. Prior to 
Fourier transformation, the Free Induction Decay (FIDs) were multiplied by an 
exponential function corresponding to a line broadening of 0.3 Hz. 1H NMR spectra were 
manually corrected for phase and baseline distortions and referenced to the TSP singlet at 
δ 0.0. Spectra were digitized using an in-house MATLAB (version R2014a, The 
Mathworks, Inc.; Natwick, MA, USA) script. Spectra were subsequently referenced to 
the internal chemical shift reference (trimethylsilyl-[2,2,3,3,-2H4]-propionate, TSP) at δ 
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0.0. Spectral regions corresponding to the internal standard (δ -0.5 to 0.5) and water (δ 
4.5 to 5.5) were excluded. 
 The serum samples were analyzed using 1H NMR spectroscopy with two different 
pulse sequences (48). The first, the so-called noesy preset sequence, provides an 
overview of all proton-containing species and yields sharp peaks for small molecule 
species, broad bands from the lipoproteins (used later for lipoprofile analysis, see below), 
and a broad largely featureless background from proteins, the most abundant being 
albumin. The second pulse sequence, the so-called Carr-Purcell-Meiboom-Gill (CPMG) 
sequence, takes advantage of the different nuclear spin relaxation times between large 
and small molecules to attenuate the peaks from large molecules (those with shorter spin-
spin relaxation times) to leave mainly small molecule metabolite peaks. The latter have 
been used for the main analysis. Experiments were performed using a standard 1D 1H 
NMR and the CPMG pulse sequence (with the form RD-90º-(t-180º-t)n-ACQ) to 
attenuate peaks from larger and more slowly moving molecules (such as lipoproteins and 
lipids) with a view to identifying low-molecular-weight metabolites. A RD of 4 s, a 
mixing time of 0.01 s, a spin-echo delay of 0.3 ms, 128 loops, and an FID ACQ of 3.067 
s were applied. A total of 32 scans were recorded into 73k data points with a spectral 
width of 20 ppm. Each spectrum was normalized to Probabilistic Quotient Normalization. 
Multivariate statistical analysis based on pattern recognition techniques such as principal 
component analysis and orthogonal partial least squares discriminant analysis (OPLS-
DA) was performed with Pareto scaling in SimcaP+14 applied to all data variables. 
OPLS-DA was used to compare independently each data set of 1H NMR metabolic 
profiles. The robustness of the models was evaluated based on R2 (explained variance) 
and Q2 (capability of prediction) values as well as sevenfold cross-validation and class 
permutation validation. 
Metabolite identifications. Confirmation of significant NMR metabolite identities was 
obtained using 1D and 2D NMR experiments (spike-in of chemical standards, J-resolved 
spectroscopy (known as JRES), TOtal Correlation SpectroscopY (known as TOCSY), 
Hetero-nuclear Single Quantum Coherence (known as HSQC) spectroscopy). 
Histological assessment of skeletal muscle fiber morphology and oxidative capacity. 
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For histological staining, serial cross-sections (10 μm) were cut from the mid-belly of the 
TA muscle, fixed in O.C.T and frozen in isopentane cooled by liquid nitrogen. 
Hematoxylin and eosin (H & E) staining was used for muscle fiber cross-sectional area 
measurements. The histochemical assay for SDH activity on the TA muscle sections was 
used to distinguish between oxidative and non-oxidative fibers, as described previously 
(50).  
Glycogen measurements in muscle.  
Glycogen content was estimated in quadriceps muscle tissues using a glycogen assay kit 
(Biovision, USA) and following the manufacturer’s instructions. 
Serum analyses.  
Serum was prepared from blood collected and stored at −70°C until assayed using the 
Roche/Hitachi 902 robot system (Roche Diagnostics, Rotkreutz, Switzerland) following 
the manufacturer’s instructions. 
Corticosterone estimation.  
Corticosterone was estimated in serum using the Corticosterone ELISA kit (Abcam) 
following the manufacturer’s instructions. 
Gene expression analysis by real-time quantitative RT-PCR (qRT-PCR).  
Total RNA was extracted from cells and muscle tissues using Trizol reagent following 
the manufacturer’s instructions. For SYBR-Green-Based qRT-PCR, isolated RNA was 
reverse-transcribed using SuperScript II and random primers (Invitrogen). qRT-PCR 
assays were performed in triplicate, and data were normalized to Rpl27 and Rpl13 and 
analyzed using qBase software. Details regarding gene-specific primers are provided in 
Supplemental Table S1. 
Mitochondrial DNA copy number quantification.  
The relative copy number of mitochondrial DNA (mtDNA) per nuclear DNA (nuDNA) 
ratio was measured by qPCR. 
Western blot analysis.  
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Tissue extracts (50 g/lane) were prepared in lysis buffer [10 mM Tris-HCl (pH 8), 150 
mM NaCl, 1% Triton X-100, and protease inhibitors and PhosSTOPTM (Roche)] and 
subjected to western blotting. The western blot was probed with anti-phospho-AMPK and 
anti-AMPK, p-ACC and ACC, p-mTOR and mTOR, p-S6 and S6 (Cell Signaling), and 
Tubulin antibodies. Immunodetection with an appropriate secondary peroxidase-
conjugated antibody (DAKO) was followed by chemiluminescence (ECL; Amersham). 
Protein band quantification was performed using LabImage software.  
Statistical analysis.  
Statistical significance was determined using GraphPad Prism 7 statistical software. For 
all experiments that required analyses between multiple groups (PF, GF and C-GF), One-
way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed. 
Two-tailed Student’s t-test was performed when observations between only two groups 
were compared. F-test was performed prior to Student’s t-test to determine equal variance 
between the two groups. P<0.05 was considered statistically significant unless otherwise 
stated. Values are expressed as mean ± SEM. 
 
Supplementary Materials 
Fig. S1. The gut microbiota  affects skeletal muscle function in mice. 
Fig. S2. The gut microbiota influences skeletal muscle oxidative capacity in mice. 
Fig. S3. A subtherapeutic dose of antibiotics affects skeletal muscle mass and function in 
mice. 
Fig. S4. Metabolomic analyses in mouse muscle, liver and serum. 
Fig. S5. Effect of the gut microbiota  on metabolic pathways in mice. 
Fig. S6. Short chain fatty acids (SCFAs) influence oxidative capacity of mouse skeletal 
muscle. 
Table S1. List of primer sequences. 
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Figure Legends  
 
Fig. 1. The gut microbiota  influences skeletal muscle mass and function in mice. (A) 
Weights of soleus, gastrocnemius, tibialis anterior (TA), quadriceps, and extensor 
digitorum longus (EDL) muscles from pathogen–free mice (PF), germ-free mice (GF), 
and germ-free mice transplanted with the gut microbiota of pathogen-free mice, referred 
to as conventionalized germ-free mice (C-GF). The number of mice used per 
experimental group: Soleus muscle (PF, n=13; GF, n=14; C-GF, n=10); gastrocnemius 
muscle (PF, n=15; GF, n=14; C-GF, n=13); TA muscle (PF, n=14; GF, n=13; C-GF, 
n=12); quadriceps muscle (PF, n=15; GF, n=14; C-GF, n=13); EDL muscle (PF, n=13; 
GF, n=12; C-GF, n=13). (B) Changes in expression of genes encoding myosin heavy 
chain (MyHC) isoforms in TA muscles of PF, GF, and C-GF mice (n=5–10 per group). 
(C) Changes in expression of Atrogin-1,  Murf-1 and FoxO3 genes in TA muscles from 
PF (n=7), GF (n=7), and C-GF (n=9) mice. (D) Shown are changes in the expression of 
genes encoding the skeletal muscle-specific transcription factors MyoD and Myogenin in 
TA muscle samples from PF (n=7), GF (n=7), and C-GF mice (n=9). (E) Shown is 
immunoblot analysis of protein lysates from TA muscles harvested from PF, GF, and C-
GF mice indicating expression of Atrogin-1 (n=4 mice per group), Murf-1 (n=4 mice per 
group), and phosphorylated AMPK (p-AMPK) (n=5 mice per group). (F) The results in 
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the histogram are expressed as the ratio of relative intensity of Atrogin-1 and Murf-1 
protein expression normalized to tubulin as loading control, and relative intensity of p-
AMPK expression relative to total AMPK expression.  
Fig.2. The gut microbiota regulates branched chain amino acid (BCAA) metabolism in 
skeletal muscle. (A) Shown are measurements of serum corticosterone concentrations in 
pathogen–free mice (PF, n=17), germ-free mice (GF, n=16), and germ-free mice 
transplanted with the gut microbiota of pathogen-free mice, referred to as 
conventionalized germ-free mice (C-GF, n=10). (B) Gene expression of Klf15 in TA 
muscles from PF (n=7), GF (n=7), and C-GF (n=9) mice. (C) Changes in expression of 
genes involved in BCAA catabolism (Bcat2, Bckdk, Bckdh) in TA muscles of PF, GF, 
and C-GF mice (n=6, 7 and 9, respectively). (D) Changes in the expression of the genes 
Igf1 and Igf binding proteins (Igfbps) in tibialis anterior muscle of PF mice ( n=7),  GF 
mice ( n=7) and C-GF mice (n=9). Data are expressed as mean ± SEM. Data are analyzed 
using ANOVA followed by Tukey’s post-hoc test and were considered statistically 
significant at *P<0.05, **P<0.01, and ***P<0.001 between indicated groups. 
 
 
Fig. 3. The gut microbiota influences the oxidative capacity of mouse skeletal 
muscle. (A)Representative images of TA muscle sections  from pathogen-free (PF), 
germ-free (GF), and germ-free mice transplanted with the gut microbiota of pathogen-
free mice, referred to as conventionalized germ-free mice (C-GF) mice stained for 
Succinic Dehydrogenase enzyme (SDH) (Scale bar, 100um). (B)  Gene expression of Sdh 
in tibialis anterior (TA) muscle from PF (n=7), GF (n=7), and C-GF mice (n=9). (C) 
Quantitative analysis of the ratio of mitochondrial DNA copy number (mtDNA) to 
nuclear DNA in gastrocnemius muscles from PF (n=4), GF (n=5), and C-GF mice (n=5). 
(D, E) Changes in expression of PGC-1α and Tfam genes (D), and CoxVa, CoxVIIb, Cyt 
c genes (E) in TA muscles of PF (n=6), GF (n=7), and C-GF mice (n=9). (F) Changes in 
expression of genes involved in glucose metabolism (Pfk, Pk, Ldh and Pdh) in TA 
muscles of  PF (n=6), GF (n=7), and C-GF mice (n=9). (G) Changes in expression of 
genes involved in the fatty acid oxidation pathway (Lcad, Mcad and Cpt1b) in TA 
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muscles of PF (n=7), GF (n=7), and C-GF (n=9) mice.  (H) Amount of glycogen in 
quadriceps muscles of PF (n=4), GF (n=3), and C-GF mice (n=4). Data are expressed as 
mean ± SEM. Statistical significance  ***P<0.001 between indicated groups. All data are 
expressed as mean±SEM. Data analysed using ANOVA followed by Tukey’s post-hoc 
test and were considered statistically significant at *P<0.05, **P<0.01, and ***P<0.001 
between indicated groups. 
 
 
 
 
Figure 4. Metabolite analysis of mouse muscle, liver and serum. (A-C) Shown is the 
average 1H NMR spectrum of hydrophilic phase after Folch extraction for 25 metabolites. 
The 1H NMR spectrum is shown for (A) gastrocnemius muscle from  pathogen-free mice 
(PF, n=8),  germ-free mice (GF, n=8) and germ-free mice transplanted with the gut 
microbiota of pathogen-free mice, referred to as conventionalized germ-free mice (C-GF 
n=10) (B) liver tissue from PF mice (n=7), GF mice (n=8) and  C-GF mice (n=10);(C) 
serum from PF mice (n=8),  GF mice (n=8), C-GF mice (n=9). Key: 1, taurocholic acid; 
2, bile acids; 3, lipid (Low Density Lipoproteins; LDL); 4, lipid (Very Low Density 
Lipoproteins; VLDL); 5, leucine; 6, 3-hydroxybutyrate; 7, alanine; 8, acetate; 9, 
glutamine; 10, glutamate; 11, pyruvate; 12, glutathione; 13, hypotaurine; 14, 
dimethylamine; 15, sarcosine; 16, trimethylamine; 17, dimethylglycine; 18, unknown 
(δ3.11) (s); 19, choline; 20, glycerophosphorylcholine; 21, taurine; 22, betaine; 23,  
glycine; 24, unknown (δ3.59) (d); 25, unknown (δ3.71) (s). Metabolites labelled in red 
were found in higher concentrations in GF mice compared to C-GF or  PF mice; 
metabolites in blue were found in lower concentrations in GF mice compared to C-GF or  
PF mice. (Key: s, singlet; d, doublet, dd, doublet of doublets; t, triplet; m, multiplet). 
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Fig. 5. Effect of the gut microbiota  on mouse neuromuscular junction (NMJ) 
proteins. (A) Changes in levels of expression of genes encoding  acetylcholine receptors 
(Chrn) in tibialis anterior muscle of PF, GF and C-GF mice including Chrna1 (PF, n=7; 
GF, n=7; C-GF, n=9), Chrnb (PF, n=7; GF, n=7; C-GF, n=8), Chrnd (PF, n=7; GF, n=7; 
C-GF, n=7) and Chrne (PF: n=7; GF: n=7; C-GF: n=7).  (B) Changes in levels of gene 
expression in tibialis anterior muscle of PF, GF and C-GF mice of receptor-associated 
protein of the synapse (Rapsyn; PF, n=7; GF, n=7; C-GF, n=9), low-density lipoprotein 
receptor–related protein 4 (Lrp4), and agrin (Agrn) (PF, n=7; GF, n=7; C-GF, n=9). (C) 
Changes in levels of the expression of the gene encoding fast-twitch troponin (Tnn) in 
tibialis anterior (TA) muscles of PF mice ( n=6); GF mice (n=7), C-GF mice (n=9). (D) 
Analysis of hindlimb muscle grip strength using the weights test in PF, GF and C-GF 
mice (n=6 per group). (E-F). Shown is the spontaneous activity of GF, PF and C-GF 
mice in the open field test measured by cumulative distance traveled (E) and cumulative 
vertical activities (F). PF mice (n=8), GF mice (n=9), and C-GF mice (n=8) were 
monitored over a 2 hour period. All data are expressed as mean ± SEM. Data were 
analysed using ANOVA followed by Tukey’s post-hoc test and were considered 
statistically significant at *P<0.05, **P<0.01, and ***P<0.001 between indicated groups. 
 
 
Fig. 5. Bacterial metabolites influence skeletal muscle function in mice. (A) Effect of 
short chain fatty acids (SCFAs) on dexamethasone (Dex)-induced muscle atrophy in 
C2C12 mouse myotubes in vitro. Differentiated myotubes were treated with a cocktail of 
SCFAs (10 mM) in the presence or absence of dexamethasone  (1 mM) for 24 hours, and 
relative gene expression of Atrogin-1 and Murf-1 was analyzed (n=3 per group). For the 
control group, myotubes were treated with solvent (0.1% DMSO) only as vehicle. (B, C) 
Effect of SCFAs on the expression of genes encoding mitochondrial proteins in C2C12 
myotubes in vitro. Differentiated myotubes were treated with a cocktail of SCFAs (10 
mM) for 24 hours and relative gene expression of (B) PGC-1α and Tfam (n=3 per group), 
and (C) CoxVa, CoxVIIb, and Cyt c were analyzed (n=3 per group). (D) Relative weights 
of soleus, gastrocnemius, tibialis anterior (TA), quadriceps, and EDL muscles from GF 
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mice either untreated or treated with SCFAs (GF+SCFAs) (n=6 mice per group). (E-G) 
Changes in gene expression of Atrogin-1,Murf-1 and MyoD (E ), PGC-1α and Tfam (F), 
and CoxVa, CoxVIIb, and Cyt c (G) in tibialis anterior (TA)  muscles from untreated and 
SCFA-treated GF mice (n=6 per group).  (H) Analysis of hindlimb muscle grip strength 
in untreated and SCFA-treated GF mice using the weights test (n=6 per group).  (I) 
Relative gene expression of Rapsyn, Lrp4, and Agrn in TA muscles from untreated and 
SCFA-treated GF mice (n=6 mice per group). All data are expressed as mean ± SEM. For 
panel A, data were analysed using ANOVA followed by Tukey’s post-hoc test. For all 
other panels, data were analysed using two-tailed Student’s t-test. Data were considered 
statistically significant at *P<0.05, **P<0.01, and ***P<0.001 between indicated groups. 
 
Table.1. Differences in metabolite concentrations between GF, PF and C-GF mice. 
 
Tissue Metabolites lower in 
GF mice 
Chemical 
shift (ppm) 
Metabolites 
higher in GF 
mice 
Chemical shift 
(ppm) 
 
Skeletal 
muscle 
Unknown 3.11 (s) Glycine 3.57 (s) 
  Alanine 1.48 (d) 
 
 
 
Liver 
Unknown 3.11 (s) Taurine 3.43 (t); 3.27 (t) 
Glutamine 2.15(m) 
2.44 (m) 
Taurocholic 
acid 
0.70 (s) 
Betaine 3.27 (s)  
3.90 (s) 
Hypotaurine 2.65 (t) 
Alanine 1.48 (d) Dimethylamine 2.72 (s) 
Leucine 0.96 (t) Sarcosine 2.74(s) 
Valine 0.99 (d)  
1.05 (d) 
 
 Pyruvate 2.39 (s) 
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Glutathione (oxidized) 2.55 (m)  
2.95 (dd) 4.57 
(q) 
Glutamate 2.35 (m) 
Glycerophosphoryl 
choline 
3.23(s) 
4.32(m) 
 
 
 
 
Serum 
Unknown 3.11 (s) Glycine 3.57 (s) 
3-hydroxybutyrate 2.39 (dd)  
2.31 (dd)  
1.2 (d) 
Lipid CH2-
C=O 
 
2.22(m) 
Trimethylamine 2.88 (s) Lipid VLDL 
CH2-CH2-CO 
2.03 (m) 
1.57 (m) 
1.29 (m) 
Valine 
 
0.99 (d)  
1.05 (d) 
  
Choline 3.21 (s) Lipid VLDL 
CH3-CH2-
CH2C= 
0.87 (t) 
Pyruvate 2.39 (s) Lipid 
CH3-
CH2(CH2)n 
1.26 (m) 
Acetate 1.91 (s)  
Dimethylglycine 2.92 (s) 
Lipid LDL (CH2)n 1.25 (m) 
Lipid LDL  
CH3-(CH2)n 
0.84 (t) 
Key: s, singlet; d, doublet, dd, doublet of doublets; t, triplet; m, multiplet 
